Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 13,586 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatoses Clear all
Withdrawn Phase 1Phase 2 Interventional

A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

NCT00627627
View directory record Official record
Conditions
Breast Cancer
Interventions
IPI-504
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Boca Raton, Florida • Lake Worth, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 24, 2026, 1:41 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

AGA Biocellular Stem/Stromal Hair Regenerative Study

NCT02849470
View directory record Official record
Conditions
Hair Disease
Interventions
Intradermal Injection in hair loss, Platelet Rich Plasma, Adipose Derived Stem/Stromal Cells, Stem/Stromal Cellular Isolation (Digestive), MatriStem Matrix (ACell) - Current Standard of Care, HD-PRP (High Density Platelet Rich Plasma), Emulsified AD-tSVF, Emulsified AD-cSVF
Procedure
Lead sponsor
Healeon Medical Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2028
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 24, 2026, 1:41 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

NCT04556773
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, Capecitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Commack, New York • Harrison, New York • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 24, 2026, 1:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations

NCT02761473
View directory record Official record
Conditions
Urticaria Pigmentosa, Cutaneous Mastocytosis
Interventions
skin biopsy, blood draw
Other
Lead sponsor
University of Minnesota
Other
Eligibility
3 Months to 23 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 24, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

NCT03004183
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
Interventions
ADV/HSV-tk, Valacyclovir, SBRT, Pembrolizumab
Biological · Drug · Radiation
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 24, 2026, 1:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

NCT05785741
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
DB-1310, Trastuzumab, Osimertinib, capecitabine
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 24, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

NCT00319254
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
SKI-606 (Bosutinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Duarte, California • Santa Monica, California • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 24, 2026, 1:41 PM EDT
Terminated No phase listed Observational

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

NCT05592483
View directory record Official record
Conditions
Breast Cancer
Interventions
None (Observational Study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
40
States / cities
Mobile, Alabama • Chandler, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 24, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant GW572016 to Treat Breast Cancer

NCT00206427
View directory record Official record
Conditions
Breast Cancer
Interventions
GW572016, lapatinib
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Albuquerque, New Mexico • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 24, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)

NCT00923169
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Anti-Transforming Growth Factor-beta (GC 1008)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Little Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 24, 2026, 1:41 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

NCT03317405
View directory record Official record
Conditions
Breast Carcinoma In Situ, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Endoxifen Hydrochloride, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 24, 2026, 1:41 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

NCT06119529
View directory record Official record
Conditions
Healthy, Atopic Dermatitis
Interventions
LY3872386, Prednisone, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Anaheim, California • Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 24, 2026, 1:41 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Lutikizumab, Placebo
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 24, 2026, 1:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Breast Tissue Bioavailability of Topically Applied Limonene

NCT01459172
View directory record Official record
Conditions
Breast Cancer
Interventions
limonene containing massage oil
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 24, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer

NCT01263145
View directory record Official record
Conditions
Adult Solid Neoplasm, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 24, 2026, 1:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Skin Health Online for Melanoma: Better Risk Assessment

NCT03130569
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Web-based Module Group
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 24, 2026, 1:41 PM EDT
Active, not recruiting Phase 4 Interventional

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

NCT06013969
View directory record Official record
Conditions
Generalized Pustular Psoriasis
Interventions
Spesolimab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Irvine, California • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 24, 2026, 1:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers

NCT01114841
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam, Vehicle Foam
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 24, 2026, 1:41 PM EDT
Not listed Phase 2 Interventional

Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery

NCT00251329
View directory record Official record
Conditions
Breast Cancer
Interventions
neoadjuvant chemotherapy
Drug
Lead sponsor
Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
6
States / cities
Jacksonville, Florida • Lakeland, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2007 · Synced Oct 24, 2026, 1:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers

NCT02647853
View directory record Official record
Conditions
Nasolabial Folds, Lipoatrophy, Lipodystrophy
Interventions
TAT4 Gel concentration A, TAT4 Gel concentration B, Placebo
Drug
Lead sponsor
Topokine Therapeutics, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 24, 2026, 1:41 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

NCT05830097
View directory record Official record
Conditions
Cancer, Breast, Cancer, Lung, Cancer of Pancreas, Cancer of Esophagus, Cancer Colorectal
Interventions
CBP-1019
Drug
Lead sponsor
Coherent Biopharma (Hefei) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Cerritos, California • Orlando, Florida • Manhasset, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 24, 2026, 1:41 PM EDT
Terminated Phase 1 Interventional

A Novel Treatment for Metastatic Melanoma

NCT00758797
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Photoimmunotherapy
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 24, 2026, 1:41 PM EDT
Completed No phase listed Observational

Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade

NCT00972010
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Sarah Blair, M.D.
Other
Eligibility
Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 24, 2026, 1:41 PM EDT
Completed Early Phase 1 Interventional

Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity

NCT00580060
View directory record Official record
Conditions
Melanoma
Interventions
GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 24, 2026, 1:41 PM EDT